Although several recent studies reported that probiotics might be beneficial for allergic\nrhinitis (AR), the effect of probiotics on AR is not consistent and have not been reproduced between\nstudies. We aimed to determine the effcacy and safety of probiotic NVP-1703, a mixture of\nBifidobacterium longum and Lactobacillus plantarum, in subjects with perennial AR. Adult subjects with\nperennial AR received either NVP-1703 (n = 47) or placebo (n = 48) for four weeks. Total nasal symptom\nscores (TNSS), rhinitis control assessment test (RCAT), blood eosinophil count, allergen-specific\nIgE, and immunological parameters in serum and urine were compared at baseline and after four\nweeks. TNSS changes from baseline at weeks 1, 3, and 4 were significant between the NVP-1703 and\nplacebo groups (p = 0.033, 0.031, and 0.029, respectively). RCAT score showed significant differences\nbetween the NVP-1703 and placebo groups (p = 0.049) at week 4. Dermatophagoides farinae-specific IgE\nlevels and serum IL-10 levels were significantly different between the NVP-1703 and placebo groups\n(p = 0.033 and p = 0.047, respectively). IL-10/IL-4 and IL-10/IL-13 ratios were different between the\nNVP-1703 and placebo groups at week 4 (p = 0.046 and 0.018, respectively). NVP-1703 treatment\nreduced urinary prostaglandin F2 and leukotriene E4 levels (p > 0.05). Therefore, NVP-1703 can be\ntreatment option for perennial AR.
Loading....